Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Armata Pharmaceuticals, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 37.18M shares outstanding
USArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology.
The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is headquartered in Marina del Rey, California.
Leadership
Daniel B. Gilmer, Ph.D.
Director
Deborah L. Birx, M.D.
Chief Executive Officer, Director
Joseph M. Patti, Ph.D.
Director
Jules Haimovitz
Director
Employees
60
Country
US
Sector
Healthcare
Website
armatapharma.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Birx Deborah | Chief Executive Officer | Automatic Sell | 14.0K | $59.8K | Jul 10, 2026 |
 Gilmer Daniel B. | Director | Grant/Award | 51.3K | -- | Apr 24, 2026 |
 Kyme Pierre | Chief Business Officer | Automatic Sell | 1.0K | $10.9K | Mar 14, 2026 |
| Birx Deborah | Chief Executive Officer | Automatic Sell | 4.9K | $51.8K | Mar 14, 2026 |
 Peterson Todd C. | Director | Grant/Award | 25.6K | -- | Mar 9, 2026 |
 Odysseas Kostas D | Director | Grant/Award | 25.6K | -- | Mar 9, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Innoviva, Inc. · joint filing· may incl. warrants· filed May 2026 | 55.5M | 82.7% as filed | 13D |
Madison Asset Management, LLC | 2.1M | 5.7% | 13F |
BlackRock, Inc. | 560.0K | 1.5% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 488.0K | 1.3% | 13F |
MILLENNIUM MANAGEMENT LLC | 470.5K | 1.3% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 270.6K | 0.7% | 13F |
Dauntless Investment Group, LLC | 203.9K | 0.5% | 13F |
 Birx Deborah Chief Executive Officer, Director | 198.4K | 0.5% | FORM 4 |
STATE STREET CORP | 129.6K | 0.3% | 13F |
NORTHERN TRUST CORP | 89.8K | 0.2% | 13F |
Insiders
- Birx DeborahChief Executive Officer
- Gilmer Daniel B.Director
- Kyme PierreChief Business Officer
- Peterson Todd C.Director
- Odysseas Kostas DDirector
- Schlesinger Sarah J.Director
- Haimovitz JulesDirector
- Kramer RobinDirector
- House David DuaneSVP, Finance, and PFO
- PATTI JOSEPH MDirector
based on 37.18M shares outstanding
US30d Avg
104.40K
60d Avg
234.81K
90d Avg
194.00K